Related Experiment Video
Updated: Jan 31, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children
Claudio Carnevale1, Luis Ferrán-De la Cierva2, Guillermo Til-Pérez1
1Department of Otolaryngology-Head and Neck Surgery and Pediatric Department, Son Espases University Hospital, Palma de Mallorca, Spain.
Insights
Systemic bevacizumab shows promise for treating aggressive recurrent respiratory papillomatosis in children. This treatment improved respiratory symptoms and quality of life with minimal side effects.
Area of Science:
- Pediatric Otolaryngology
- Medical Oncology
Background:
- Recurrent respiratory papillomatosis (RRP) is a rare, aggressive childhood disease with severe respiratory consequences.
- Current treatments for RRP lack proven efficacy, necessitating novel therapeutic approaches.
Observation:
- Two children with severe, aggressive RRP were treated with systemic bevacizumab.
- Treatment led to dramatic improvements in respiratory symptoms and overall quality of life.
Findings:
- Systemic bevacizumab demonstrated significant efficacy in managing aggressive RRP.
- The treatment was well-tolerated, with mild proteinuria as the only noted complication.
Implications:
- Systemic bevacizumab represents a promising adjuvant therapy for pediatric aggressive RRP.
- Further research is warranted to determine optimal dosing and treatment duration for bevacizumab in RRP.
Abstract:
Recurrent respiratory papillomatosis can be a devastating condition for a child, with severe consequences. Currently, there is no proven successful medical treatment. We describe the use of systemic bevacizumab to treat two children affected by aggressive recurrent respiratory papillomatosis. Respiratory symptoms and quality of life improved dramatically in both patients, without observing any toxicity. The only complication was mild proteinuria. Systemic bevacizumab is a promising adjuvant treatment in aggressive recurrent respiratory papillomatosis in children. It is effective and well tolerated. Further studies are needed to establish the optimal dosing frequency and duration of therapy. Laryngoscope, 129:1001-1004, 2019.
Related Concept Videos
Guidelines and Strategies for Safe Computer Charting
Maintain Confidentiality and Security:
Anatomy of Respiratory System II: Lower Respiratory Tract
The Larynx
It is located between the pharynx and the trachea, acts as a passageway for air, and hosts several critical structures, such as the epiglottis, vocal cords, and glottis. The epiglottis acts as a gateway, guiding food to the...
The Respiratory System
Anatomy of Respiratory System I: Upper Respiratory Tract
Nose and nasal cavity
The nose and nasal cavity represent the main external openings of the respiratory tract....
Second Order systems II
Respiratory Capacities
One key metric is the Inspiratory Capacity (IC), which represents the maximum amount of air that can be inhaled with full effort. IC is calculated by summing the tidal volume and inspiratory reserve volume, typically ranging from 2.4 to 3.6 liters.
The Functional Residual Capacity (FRC) represents the air in the...

